News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clovis Oncology (CLVS)'s CO-1686 Continues to Demonstrate Promising Clinical Activity and Safety in Updated Phase I Study Results


10/28/2013 10:40:45 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SYDNEY--(BUSINESS WIRE)--Clovis Oncology (NASDAQ:CLVS) announced today updated findings from the Phase I portion of its ongoing Phase I/II clinical study of CO-1686, the Company’s novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. Interim results from the Phase I dose-escalation portion of this Phase I/II study are being presented today in an oral presentation by Professor Jean-Charles Soria at the IASLC 15th World Conference on Lung Cancer in Sydney.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES